Prognostic factors in the nonsurgical treatment of esophageal carcinoma with radiotherapy or radiochemotherapy: The importance of pretreatment hemoglobin levels

Cancer

Volumn 103, Issue 8, 2005, Pages 1740-1746

  Rades, Dirk ^a   Schild, Steven E ^b   Bahrehmand, Roja ^a   Zschenker, Oliver ^a   Alberti, Winfried A ^a   Rudat, Volker R ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b MAYO CLINIC   (United States)

Author keywords

Esophageal carcinoma; Pretreatment hemoglobin level; Prognostic factors; Radiotherapy

Indexed keywords

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER GRADING; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CONSERVATIVE TREATMENT; CONTROLLED STUDY; ESOPHAGUS CARCINOMA; FEMALE; GENDER; HAZARD ASSESSMENT; HEMOGLOBIN DETERMINATION; HISTOLOGY; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIVARIATE ANALYSIS; OUTCOMES RESEARCH; PERFORMANCE; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE; RETROSPECTIVE STUDY; TREATMENT FAILURE; TUMOR LOCALIZATION; TUMOR VOLUME;

ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; ESOPHAGEAL NEOPLASMS; FEMALE; HEMOGLOBINS; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RADIOTHERAPY DOSAGE; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 16844385108     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20952     Document Type: Article

References (24)

1. Daly JM, Fry WA, Little AG, et al. Esophageal: results of an American College of Surgeons patient care evaluation study. J Am Coll Surg. 2000;190:562-573.
2. Eloubeidi MA, Desmond R, Arguedas MR, Reed CE, Wilcox CM. Prognostic factors for the survival of patients with esophageal carcinoma in the U.S. The importance of tumor length and lymph node status. Cancer. 2002;95:1434-1443.
3. Polee MB, Hop WCJ, Kok TC, et al. Prognostic factors for survival in patients with advanced esophageal cancer treated with cisplatin-based combination chemotherapy. Br J Cancer. 2003;89:2045-2050.
4. Kodaira T, Fuwa N, Itoh Y, et al. Multivariate analysis of treatment outcome in patients with esophageal carcinoma treated with definitive radiotherapy. Am J Clin Oncol. 2003;26:392-397.
5. Richmond J, Seydel HG, Bae Y, Lewis J, Burdakin J, Jacobsen G. Comparison of three treatment strategies for esophageal cancer within a single institution. Int J Radiat Oncol Biol Phys. 1987;13:1617-1620.
6. Jeremic B, Shibamoto Y, Acimovic L, et al. Accelerated hyperfractionated radiation therapy and concurrent 5-fluorouracil/cisplatin chemotherapy for locoregional squamous cell carcinoma of the thoracic esophagus: a phase II study. Int J Radiat Oncol Biol Phys. 1998;40:1061-1066.
7. Rudat V, Dietz A, Schramm O, et al. Prognostic impact of total tumor volume and hemoglobin concentration on the outcome of patients with advanced head and neck cancer after concomitant boost radiochemotherapy. Radiother Oncol. 1999;53:119-125.
8. Becker A, Stadler P, Lavay RS, et al. Severe anemia is associated with poor tumor oxygenation in head and neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys. 2000;46:459-466.
9. Langendijk H, de Jong J, Wanders R, Lambin P, Slotman B. The importance of pre-treatment hemoglobin level in inoperable non-small cell lung carcinoma treated with radical radiotherapy. Radiother Oncol. 2003;67:321-325.
10. Vaupel P, Thews O, Mayer A, Hockel S, Hockel M. Oxygenation status of gynecologic tumors: what is the optimal hemoglobin level? Strahlenther Onkol. 2002;178:727-731.
11. Barendsen GW. Dose fractionation, dose rate and iso-effect relationships for normal tissue responses. Int J Radiat Oncol Biol Phys. 1982;8:1981-1997.
12. Joiner MC, Van der Kogel AJ. The linear-quadratic approach to fractionation and calculation of isoeffect relationships. In: Steel GG, editor. Basic clinical radiobiology. 2nd ed. New York: Oxford University Press, 1997:106-112.
13. Urba SG, Orringer MB, Ianettonni M, Hayman, JA, Satoru H. Concurrent cisplatin, paclitaxel, and radiotherapy as preoperative treatment for patients with locoregional esophageal carcinoma. Cancer. 2003;98:2177-2183.
14. Kaplan EL, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
15. Minsky BD, Pajak TF, Ginsberg RJ, et al. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol. 2002;20:1167-1174.
16. Sun DR. Ten-year follow up of esophageal cancer treated by radical radiation therapy: analysis of 869 patients. Int J Radiat Oncol Biol Phys. 1989;16:329-334.
17. Burmeister BH, Denham JW, O'Brien M, et al. Combined modality therapy for esophageal carcinoma: preliminary results from a large Australasian multicenter study. Int J Radiat Oncol Biol Phys. 1995;32:997-1006.
18. Herskovic A, Martz K, Al-Sarraf M, et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med. 1992;326:1593-1598.
19. Cooper JS, Guo MD, Herskovic A, et al. Chemoradiotherapy of locally advanced esophageal cancer. Long-term follow up of a prospective randomized trial. JAMA. 1999;281:1623-1627.
20. Wong R, Malthaner RA, Zuraw L, Rumble RB. Combined modality radiotherapy and chemotherapy in nonsurgical management of localized carcinoma of the esophagus: a practice guideline. Int J Radiat Oncol Biol Phys. 2003;55:930-942.
21. Coia LR, Minsky BD, Berkey BA, et al. Outcome of patients receiving radiation for cancer of the oesophagus: results of the 1992-1994 patterns of care study. J Clin Oncol 2000;18:455-462.
22. Sarbia M, Stahl M, Fink U, et al. Prognostic significance of cyclin D1 in esophageal squamous cell carcinoma patients treated by surgery alone or combined therapy modalities. Int J Cancer. 1999;84:86-91.
23. Ikeda G, Isaji S, Chandra B, Watanabe M, Kawarada Y. Prognostic significance of biologic factors in squamous cell carcinoma of the oesophagus. Cancer. 1999;86:1396-1405.
24. Shimada H, Takeda A, Nabeya Y, et al. Clinical significance of serum vascular endothelial growth factor in oesophageal squamous cell carcinoma. Cancer. 2000;92:663-669.